Glipizide, primarily marketed in the US by Pfizer under the trade name Glucotrol, is an oral rapid- and short-acting anti-diabetic medication from the sulfonylurea class. It is classified as a second-generation sulfonylurea, which means that it undergoes enterohepatic circulation. Second-generation sulfonylureas are both more potent and have shorter half-lives than the first-generation sulfonylureas.Wikipedia
The US FDA includes a precautionary warning on Glipizide/Glucotrol for individuals with G6PD deficiencies due to the risk for hemolytic anemia, and non-sulfonylurea alternatives should be considered.
|Genotype/Genoset||Diplotype||Gene||Drug Use/Category/Class||Medical Field||Summary||Descriptive Sentence|
|gs309||WT/WT||G6PD||Diabetes||Endocrinology||Normal Response Expected||You do not appear to carry any G6PD mutations linked to an unwanted side effect (hemolytic anemia).|
|gs307||Carrier||G6PD||Diabetes||Endocrinology||Consider Alternatives||You carry a G6PD mutation that might lead to an unwanted side effect (hemolytic anemia) when taking glipizide; due to variable expression (i.e. in females), enzymatic testing for G6PD activity is advisable.|
|gs308||G6PD-deficient||G6PD||Diabetes||Endocrinology||Consider Alternatives||You carry a G6PD mutation linked to an unwanted side effect (hemolytic anemia) when taking glipizide; non-sulfonylurea alternatives should be considered.|